Study identification

EU PAS number

EUPAS1000000713

Study ID

1000000713

Official title and acronym

Effectiveness and immunogenicity of respiratory syncytial virus vaccine (RSVpreF from Pfizer) for pregnant persons: A living systematic review and meta-analysis

DARWIN EU® study

No

Study countries

Argentina

Study description

The study design is a Living Systematic Review (LSR) and meta-analysis to evaluate the effectiveness and immunogencity of RSVpreF maternal vaccine in infants and the effectiveness of the RSVpreF maternal vaccine in pregnant and postpartum individuals.
The study will follow the Cochrane and WHO methods, and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA) statement.
The LSR was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database under number CRD CRD420251077829, following the PRISMA-P statement.
The LSR and meta-analysis design was selected due to the ability to synthesize evidence continually, so the most recent, relevant and reliable evidence can be used to inform policy and practice.
All systematic reviews processes have been enhanced using the web-based powered by artificial intelligence (AI).

Study status

Ongoing
Research institutions and networks

Institutions

Instituto de Efectividad Clínica y Sanitaria A. Civil (IECS)

Contact details

Dr. Mabel Berrueta

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Pfizer Inc.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable